Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just jumped back in here at 38.65
Looking for a bounce during the next two sessions
I agree that's it more likely to be stop losses being triggered.
SNGX
Stops being triggered now
Starting to look attractive again down here.
I think we go lower on Greece but she will bounce back
Looking for good re-entry point
Agree 100%
It really moves a lot now, both ways, with little volume.
I just bought another block
TNXP
Still undervalued down here.
Should move up nicely now after consolidating lower IMO
Didn't get there but it has continued to accumulate well.
2.17% up day today was very nice.
TNXP
Nice recovery today.
Headed back over $10 soon IMO
Getting brought down here fairly effectively
Seems like everything is on sale.
These next few days should be good buying days
TNXP
Tonix Pharma (TNXP) Fair Value Raised to $12 at Janney Capital
June 29, 2015 6:55 AM
Janney Capital analyst Chiara Russo reiterated a Buy rating and adjusted its fair value target on Tonix Pharma (NASDAQ: TNXP) to $12.00 (from $10.00), saying non-clinical study supports TNX-201 in headache.
Russon commented, "We spent some time with Tonix CEO Seth Lederman this week following their poster presentations at the Annual Scientific Meeting of the American Headache Society. Though non-clinical in nature, one poster in particular caught our eye as it supports the development of TNX-201 in tension headache as the isolated (R)-isomer of isometheptene decreased trigeminal (cranial nerve) pain in not one, but two established rat models."
I bought back in at 8.80
GLTA
TNXP
Tonix Pharma (TNXP) Fair Value Raised to $12 at Janney Capital
June 29, 2015 6:55 AM
Janney Capital analyst Chiara Russo reiterated a Buy rating and adjusted its fair value target on Tonix Pharma (NASDAQ: TNXP) to $12.00 (from $10.00), saying non-clinical study supports TNX-201 in headache.
Russon commented, "We spent some time with Tonix CEO Seth Lederman this week following their poster presentations at the Annual Scientific Meeting of the American Headache Society. Though non-clinical in nature, one poster in particular caught our eye as it supports the development of TNX-201 in tension headache as the isolated (R)-isomer of isometheptene decreased trigeminal (cranial nerve) pain in not one, but two established rat models."
TNXP
Bought back in at 8.80
I agree.
It's just profit taking
Ready for the eventual move back up
LOS ANGELES, CA (June 24, 2015) – Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it will join the Russell Global Index on June 26, according to a list of final additions posted June 19 on the FTSE Russell website.
LBIO
http://t.co/7Sc8ZdV6No
joining the Russell Global Index.
I sold a few days ago
I don't remember exactly when
I did but I sold around .75
I just bought back my LBIO at 9.05
I just can't see it falling much lower.
Should be north of $10 soon IMO
TNXP
I just bought back 1/3 of my original position at 9.44
IMO, this is headed back up soon
Just bought the dip here.
I agree this is very undervalued and today is just a great buying opportunity IMHO
What are your thoughts on TNXP?
I sold high and was looking at buying back in down here in the 9.40's
Me too
Exactly 2.58
"Our findings that TNX-201 selectively modulates a receptor in the central nervous system that appears to regulate pain perception and responses, together with positive data in two rodent models representative of migraine, support the development of TNX-201 as a therapeutic for headache and potentially other pain indications and one that may be differentiated from currently-approved products," said Bruce Daugherty, Ph.D., Tonix's chief scientific officer. "We look forward to reporting the results of our Phase 2 POC study in episodic tension-type headache in the fourth quarter of this year."
I agree, IMO, this still has a good ways to run!
Congrats!!!
TNXP
"Our findings that TNX-201 selectively modulates a receptor in the central nervous system that appears to regulate pain perception and responses, together with positive data in two rodent models representative of migraine, support the development of TNX-201 as a therapeutic for headache and potentially other pain indications and one that may be differentiated from currently-approved products," said Bruce Daugherty, Ph.D., Tonix's chief scientific officer. "We look forward to reporting the results of our Phase 2 POC study in episodic tension-type headache in the fourth quarter of this year."
This still has a ways to run IMHO!
TNXP
These dips have been money every time.
Buying the dips!
STEM
Headed up this week in my opinion.
http://t.co/j0AhItuNvs
That dip into the 9.60's today was awesome.
I grabbed some more in the low 9.80's
I believe we are headed into the 10.50's-10.60's next week
IMHO of course
Yes
I'm still holding TPIV
It still has room to run IMO
Yes
This one is a textbook example of buying the dips!
It will be fun to see it around $12-14 over the next month or so
IMO
I agree with holding. This has a lot further to go IMO.
This is the day traders taking profits here.
Great place to buy the dip here at 9.80's IMO
Never saw that coming.
Started the day well
Nope
On to the next one
Stopped out again.
Wow
Pullbacks like this could be a great opportunity for some here?